Multislice	O
Analysis	O
of	O
Blood	O
Flow	O
Values	O
in	O
CT	O
Perfusion	O
Studies	O
of	O
Lung	B-DS
Cancer	I-DS

Academic	O
Editor	O
:	O
Noriyoshi	O
Sawabata	O

Objectives	O
.	O

Tumour	B-DS
heterogeneity	O
represents	O
a	O
key	O
issue	O
in	O
CT	O
perfusion	O
(	O
CTp	O
),	O
where	O
all	O
studies	O
are	O
usually	O
based	O
on	O
global	O
mean	O
or	O
median	O
values	O
of	O
perfusion	O
maps	O
,	O
often	O
computed	O
on	O
whole	O
tumour	B-DS
.	O

We	O
sought	O
to	O
determine	O
whether	O
,	O
and	O
to	O
what	O
extent	O
,	O
such	O
global	O
values	O
can	O
be	O
representative	O
of	O
tumour	B-DS
heterogeneity	O
,	O
with	O
respect	O
to	O
single	O
slices	O
,	O
and	O
could	O
be	O
used	O
for	O
therapy	O
assessment	O
.	O
Materials	O
and	O
Methods	O
.	O

Twelve	O
patients	O
with	O
one	O
primary	O
non	B-DS
-	I-DS
small	I-DS
cell	I-DS
lung	I-DS
cancer	I-DS
lesion	O
were	O
enrolled	O
in	O
this	O
study	O
,	O
for	O
a	O
total	O
amount	O
of	O
26	O
CTp	O
examinations	O
and	O
118	O
slices	O
.	O

Mean	O
and	O
median	O
blood	O
flow	O
(	O
BF	O
)	O
values	O
,	O
calculated	O
voxel	O
-	O
based	O
,	O
were	O
computed	O
on	O
each	O
slice	O
and	O
the	O
whole	O
tumour	B-DS
.	O

To	O
measure	O
functional	O
heterogeneity	O
,	O
entropy	O
was	O
calculated	O
on	O
BF	O
values	O
as	O
well	O
.	O
Results	O
.	O

Most	O
of	O
the	O
slices	O
were	O
not	O
represented	O
by	O
the	O
global	O
BF	O
values	O
computed	O
on	O
the	O
whole	O
tumour	B-DS
.	O

In	O
addition	O
,	O
there	O
are	O
a	O
number	O
of	O
lesions	O
having	O
equivalent	O
global	O
BF	O
values	O
,	O
but	O
they	O
are	O
composed	O
of	O
slices	O
having	O
very	O
different	O
heterogeneity	O
distributions	O
,	O
that	O
is	O
,	O
entropy	O
values	O
.	O
Conclusions	O
.	O

Global	O
mean	O
/	O
median	O
BF	O
values	O
of	O
the	O
single	O
slices	O
separately	O
should	O
be	O
considered	O
for	O
clinical	O
assessment	O
,	O
only	O
if	O
interpreted	O
through	O
entropy	O
computed	O
on	O
BF	O
values	O
.	O

The	O
numerical	O
equivalence	O
between	O
global	O
BF	O
values	O
of	O
different	O
lesions	O
may	O
correspond	O
to	O
different	O
clinical	O
status	O
,	O
thus	O
inducing	O
possible	O
errors	O
in	O
choice	O
of	O
therapy	O
when	O
considering	O
global	O
values	O
only	O
.	O

1	O
.	O

Introduction	O

The	O
introduction	O
of	O
antiangiogenic	O
therapies	O
aiming	O
at	O
preventing	O
or	O
regularizing	O
the	O
growth	O
of	O
vascularization	O
in	O
cancer	B-DS
tissues	O
has	O
aroused	O
lively	O
interest	O
around	O
promising	O
imaging	O
techniques	O
capable	O
of	O
detecting	O
vascular	O
changes	O
,	O
thus	O
providing	O
fundamental	O
information	O
about	O
treatments	O
effectiveness	O
before	O
the	O
appearance	O
of	O
morphological	O
changes	O
.	O

In	O
the	O
last	O
few	O
years	O
,	O
computed	O
tomography	O
perfusion	O
(	O
CTp	O
)	O
has	O
gained	O
a	O
large	O
consensus	O
among	O
researchers	O
,	O
thanks	O
to	O
its	O
capability	O
of	O
providing	O
both	O
high	O
morphological	O
resolution	O
images	O
and	O
functional	O
information	O
about	O
the	O
investigated	O
tissues	O
[	O
1	O
].	O

This	O
noninvasive	O
and	O
widely	O
available	O
methodology	O
allows	O
obtaining	O
time	O
concentration	O
curves	O
(	O
TCCs	O
)	O
pertaining	O
to	O
a	O
specific	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
by	O
repeatedly	O
acquiring	O
the	O
same	O
portion	O
of	O
tissue	O
during	O
,	O
and	O
after	O
,	O
the	O
intravenous	O
injection	O
of	O
an	O
iodinated	O
contrast	O
agent	O
[	O
2	O
].	O

Through	O
the	O
analysis	O
of	O
TCCs	O
,	O
it	O
is	O
possible	O
to	O
achieve	O
colorimetric	O
maps	O
representing	O
values	O
of	O
perfusion	O
parameters	O
that	O
can	O
be	O
used	O
for	O
multiple	O
purposes	O
such	O
as	O
monitoring	O
vascular	O
changes	O
after	O
the	O
administration	O
of	O
antiangiogenic	O
drugs	O
[	O
3	O
],	O
predicting	O
tumour	B-DS
response	O
[	O
4	O
,	O
5	O
],	O
or	O
differentiating	O
tumour	B-DS
subtypes	O
[	O
6	O
].	O

Several	O
sources	O
of	O
variability	O
are	O
known	O
to	O
affect	O
the	O
reliability	O
of	O
final	O
perfusion	O
parameters	O
[	O
7	O
]	O
that	O
from	O
time	O
to	O
time	O
have	O
also	O
prompted	O
the	O
scientific	O
community	O
to	O
argue	O
about	O
the	O
effectiveness	O
of	O
CTp	O
[	O
1	O
,	O
8	O
].	O

Indeed	O
,	O
when	O
investigating	O
the	O
possible	O
clinical	O
applications	O
,	O
tumour	B-DS
heterogeneity	O
,	O
representativeness	O
of	O
tumour	B-DS
regions	O
,	O
reliability	O
of	O
results	O
,	O
and	O
reproducibility	O
of	O
CTp	O
examinations	O
represent	O
different	O
as	O
well	O
as	O
interconnected	O
issues	O
that	O
should	O
be	O
addressed	O
as	O
a	O
whole	O
.	O

In	O
fact	O
,	O
heterogeneity	O
is	O
an	O
intrinsic	O
characteristic	O
of	O
all	O
tumours	B-DS
[	O
9	O
,	O
10	O
],	O
at	O
several	O
levels	O
,	O
ranging	O
from	O
genes	O
to	O
tissues	O
[	O
11	O
],	O
and	O
this	O
is	O
also	O
reflected	O
in	O
the	O
hemodynamic	O
behaviour	O
,	O
for	O
instance	O
,	O
in	O
areas	O
of	O
angiogenesis	O
and	O
necrosis	O
[	O
12	O
].	O

As	O
a	O
consequence	O
,	O
which	O
part	O
of	O
the	O
tumour	B-DS
could	O
be	O
the	O
most	O
representative	O
one	O
for	O
clinical	O
assessments	O
has	O
been	O
widely	O
debated	O
.	O

Traditionally	O
,	O
the	O
first	O
CTp	O
examinations	O
were	O
performed	O
on	O
one	O
slice	O
,	O
due	O
to	O
technology	O
limitation	O
of	O
data	O
acquisition	O
and	O
processing	O
apparatuses	O
[	O
13	O
].	O

Afterwards	O
,	O
the	O
improvement	O
of	O
technology	O
has	O
permitted	O
working	O
on	O
the	O
whole	O
tumour	B-DS
[	O
14	O
],	O
or	O
groups	O
of	O
slices	O
,	O
as	O
the	O
central	O
ones	O
[	O
15	O
].	O

However	O
,	O
authors	O
have	O
still	O
continued	O
working	O
on	O
a	O
single	O
section	O
only	O
[	O
16	O
],	O
chosen	O
as	O
the	O
one	O
representing	O
the	O
largest	O
tumour	B-DS
diameter	O
[	O
17	O
],	O
or	O
better	O
incorporated	O
the	O
solid	O
-	O
appearing	O
part	O
of	O
the	O
target	O
lesion	O
[	O
18	O
],	O
or	O
else	O
being	O
in	O
the	O
middle	O
scan	O
position	O
[	O
19	O
–	O
21	O
].	O

Nonetheless	O
,	O
several	O
researchers	O
choose	O
the	O
single	O
tumour	B-DS
section	O
based	O
on	O
visual	O
considerations	O
only	O
[	O
22	O
],	O
such	O
as	O
that	O
having	O
the	O
best	O
quality	O
[	O
23	O
],	O
or	O
the	O
widest	O
area	O
[	O
24	O
],	O
jointly	O
to	O
the	O
least	O
variability	O
[	O
25	O
].	O

Undoubtedly	O
,	O
the	O
most	O
important	O
issue	O
to	O
make	O
CTp	O
entering	O
the	O
clinical	O
practice	O
is	O
the	O
possibility	O
of	O
achieving	O
between	O
-	O
patient	O
and	O
among	O
-	O
patients	O
standardization	O
.	O

To	O
this	O
purpose	O
,	O
the	O
reproducibility	O
of	O
reliable	O
results	O
is	O
an	O
essential	O
requirement	O
,	O
but	O
it	O
must	O
be	O
coupled	O
to	O
the	O
clinical	O
representativeness	O
of	O
numerical	O
results	O
.	O

In	O
the	O
literature	O
,	O
it	O
has	O
been	O
widely	O
stated	O
that	O
by	O
considering	O
the	O
whole	O
tumour	B-DS
[	O
26	O
],	O
or	O
even	O
group	O
of	O
slices	O
[	O
27	O
],	O
perfusion	O
parameters	O
may	O
improve	O
reproducibility	O
and	O
repeatability	O
[	O
28	O
],	O
against	O
a	O
single	O
slice	O
.	O

That	O
is	O
,	O
considering	O
a	O
wider	O
“	O
population	O
”	O
(	O
i	O
.	O
e	O
.,	O
more	O
slices	O
),	O
averaging	O
values	O
helps	O
achieving	O
a	O
“	O
global	O
”	O
tumour	B-DS
behaviour	O
.	O

Using	O
global	O
mean	O
or	O
median	O
values	O
can	O
also	O
work	O
for	O
diagnosis	O
purposes	O
,	O
where	O
CTp	O
has	O
been	O
used	O
to	O
discriminate	O
between	O
benign	O
and	O
malignant	O
in	O
different	O
types	O
of	O
lung	O
lesions	O
,	O
including	O
pulmonary	O
solitary	O
nodules	O
.	O

For	O
instance	O
,	O
the	O
overall	O
mean	O
of	O
pulmonary	O
index	O
,	O
pulmonary	O
and	O
bronchial	O
blood	O
flow	O
(	O
BF	O
),	O
is	O
computed	O
on	O
multiple	O
slices	O
in	O
[	O
29	O
]	O
and	O
on	O
three	O
tumour	B-DS
sections	O
chosen	O
according	O
to	O
the	O
axial	O
,	O
coronal	O
,	O
and	O
sagittal	O
planes	O
,	O
in	O
[	O
30	O
].	O

The	O
overall	O
median	O
of	O
all	O
the	O
CTp	O
parameters	O
for	O
the	O
whole	O
tumour	B-DS
is	O
computed	O
in	O
[	O
14	O
],	O
where	O
the	O
median	O
was	O
preferred	O
over	O
the	O
mean	O
operator	O
to	O
avoid	O
outliers	O
.	O

All	O
the	O
studies	O
considered	O
refer	O
to	O
global	O
perfusion	O
parameters	O
,	O
whether	O
they	O
are	O
mean	O
or	O
median	O
values	O
,	O
encompassing	O
all	O
the	O
tumour	B-DS
characteristics	O
.	O

However	O
,	O
in	O
this	O
way	O
,	O
besides	O
the	O
uncertainty	O
intrinsic	O
to	O
the	O
CTp	O
acquisition	O
and	O
processing	O
procedure	O
,	O
global	O
parameters	O
also	O
reduce	O
the	O
variability	O
due	O
to	O
tumour	B-DS
heterogeneity	O
.	O

This	O
is	O
acknowledged	O
by	O
several	O
authors	O
,	O
which	O
recognize	O
that	O
global	O
values	O
only	O
provide	O
an	O
overall	O
measure	O
of	O
variability	O
[	O
31	O
]	O
and	O
that	O
“	O
may	O
not	O
be	O
optimal	O
for	O
tumour	B-DS
evaluation	O
prior	O
to	O
treatment	O
or	O
therapy	O
response	O
evaluation	O
”	O
[	O
32	O
].	O

Nevertheless	O
,	O
very	O
few	O
attempts	O
have	O
been	O
made	O
to	O
try	O
assessing	O
the	O
capability	O
of	O
CTp	O
parameters	O
to	O
evaluate	O
the	O
treatment	O
response	O
of	O
patients	O
with	O
non	B-DS
-	I-DS
small	I-DS
cell	I-DS
lung	I-DS
cancer	I-DS
(	O
NSCLC	B-DS
),	O
but	O
the	O
lack	O
of	O
reproducibility	O
could	O
not	O
confirm	O
the	O
results	O
.	O

For	O
instance	O
,	O
the	O
study	O
in	O
[	O
33	O
],	O
dealing	O
with	O
CTp	O
monitoring	O
of	O
antiangiogenic	O
therapies	O
in	O
lung	B-DS
cancer	I-DS
,	O
concludes	O
that	O
CTp	O
can	O
detect	O
therapy	O
-	O
induced	O
changes	O
in	O
perfusion	O
,	O
but	O
the	O
lack	O
of	O
reproducibility	O
depletes	O
these	O
findings	O
.	O

Similar	O
outcomes	O
regarding	O
the	O
CTp	O
capability	O
of	O
monitoring	O
antiangiogenic	O
therapies	O
were	O
reported	O
in	O
[	O
4	O
],	O
even	O
though	O
,	O
in	O
this	O
case	O
,	O
no	O
reproducibility	O
studies	O
have	O
been	O
performed	O
.	O

On	O
the	O
other	O
hand	O
,	O
more	O
recently	O
the	O
authors	O
in	O
[	O
24	O
]	O
could	O
not	O
find	O
any	O
correlation	O
between	O
CTp	O
parameters	O
and	O
survival	O
of	O
patients	O
treated	O
with	O
antiangiogenic	O
therapies	O
and	O
chemotherapy	O
.	O

Also	O
,	O
they	O
concluded	O
that	O
entropy	O
only	O
,	O
computed	O
on	O
the	O
Hounsfield	O
units	O
(	O
HU	O
),	O
could	O
be	O
considered	O
as	O
an	O
independent	O
prognostic	O
factor	O
for	O
overall	O
survival	O
(	O
OS	O
),	O
this	O
suggesting	O
the	O
importance	O
of	O
tumour	B-DS
heterogeneity	O
in	O
assessing	O
tumour	B-DS
aggressiveness	O
.	O

While	O
it	O
is	O
widely	O
agreed	O
that	O
considering	O
tumour	B-DS
volumes	O
give	O
more	O
information	O
than	O
using	O
a	O
single	O
slice	O
,	O
usually	O
single	O
slices	O
are	O
merged	O
together	O
to	O
provide	O
global	O
parameters	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
investigate	O
the	O
clinical	O
representativeness	O
of	O
global	O
perfusion	O
values	O
and	O
to	O
assess	O
their	O
capability	O
to	O
deal	O
with	O
tumour	B-DS
heterogeneity	O
.	O

To	O
this	O
purpose	O
,	O
an	O
extensive	O
analysis	O
is	O
carried	O
out	O
on	O
a	O
wide	O
set	O
of	O
118	O
tumour	B-DS
slices	O
,	O
and	O
on	O
corresponding	O
whole	O
tumours	B-DS
,	O
referring	O
to	O
12	O
baseline	O
and	O
14	O
follow	O
-	O
up	O
(	O
FU	O
)	O
examinations	O
.	O

BF	O
values	O
for	O
each	O
voxel	O
of	O
the	O
various	O
tumour	B-DS
sections	O
were	O
calculated	O
and	O
showed	O
through	O
the	O
use	O
of	O
colorimetric	O
maps	O
.	O

Global	O
mean	O
and	O
median	O
BF	O
values	O
of	O
each	O
slice	O
and	O
of	O
the	O
whole	O
tumour	B-DS
were	O
then	O
computed	O
.	O

In	O
order	O
to	O
measure	O
hemodynamic	O
heterogeneity	O
,	O
entropy	O
was	O
computed	O
on	O
the	O
BF	O
values	O
of	O
each	O
colorimetric	O
map	O
and	O
of	O
each	O
lesion	O
.	O

The	O
entropy	O
is	O
a	O
well	O
-	O
known	O
measure	O
of	O
the	O
information	O
content	O
[	O
34	O
]	O
and	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
time	O
that	O
the	O
entropy	O
is	O
computed	O
on	O
BF	O
maps	O
.	O

Therefore	O
,	O
in	O
this	O
work	O
the	O
entropy	O
is	O
also	O
a	O
measure	O
of	O
the	O
representativeness	O
of	O
the	O
information	O
content	O
conveyed	O
by	O
a	O
BF	O
map	O
.	O

The	O
first	O
statistical	O
analysis	O
was	O
carried	O
out	O
to	O
exclude	O
that	O
the	O
groups	O
of	O
single	O
slices	O
composing	O
the	O
respective	O
whole	O
tumours	B-DS
had	O
the	O
same	O
mean	O
or	O
median	O
value	O
.	O

Then	O
,	O
a	O
second	O
analysis	O
was	O
executed	O
to	O
assess	O
whether	O
some	O
slices	O
exist	O
with	O
the	O
same	O
mean	O
or	O
median	O
global	O
BF	O
values	O
as	O
the	O
whole	O
tumour	B-DS
,	O
so	O
as	O
to	O
find	O
out	O
which	O
perfusion	O
pattern	O
,	O
at	O
several	O
levels	O
,	O
is	O
represented	O
by	O
the	O
global	O
values	O
of	O
whole	O
tumours	B-DS
.	O

In	O
addition	O
,	O
being	O
each	O
slice	O
endowed	O
with	O
its	O
own	O
entropy	O
value	O
,	O
it	O
is	O
also	O
possible	O
to	O
assess	O
the	O
heterogeneity	O
those	O
selected	O
slices	O
own	O
.	O

To	O
complete	O
the	O
analyses	O
,	O
a	O
comparison	O
between	O
tumours	B-DS
with	O
same	O
global	O
mean	O
or	O
median	O
BF	O
values	O
was	O
performed	O
,	O
so	O
as	O
to	O
verify	O
whether	O
,	O
and	O
to	O
what	O
extent	O
,	O
a	O
statistical	O
equivalence	O
of	O
global	O
perfusion	O
values	O
hints	O
at	O
similar	O
perfusion	O
patterns	O
and	O
heterogeneity	O
features	O
.	O

During	O
data	O
analysis	O
,	O
the	O
results	O
achieved	O
for	O
baseline	O
and	O
FU	O
examinations	O
are	O
kept	O
separate	O
in	O
order	O
to	O
allow	O
detecting	O
possible	O
differences	O
between	O
untreated	O
lesions	O
,	O
preserving	O
their	O
natural	O
vascular	O
structure	O
,	O
and	O
lesions	O
whose	O
vascular	O
network	O
has	O
been	O
modified	O
by	O
the	O
action	O
of	O
antiangiogenic	O
treatments	O
.	O

2	O
.	O

Materials	O
and	O
Methods	O

This	O
retrospective	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
.	O

Twenty	O
-	O
two	O
patients	O
(	O
fifteen	O
men	O
,	O
seven	O
women	O
,	O
mean	O
age	O
64	O
.	O
7	O
years	O
,	O
range	O
42	O
–	O
81	O
years	O
)	O
with	O
one	O
primary	O
NSCLC	B-DS
lesion	O
underwent	O
CTp	O
.	O

Patients	O
over	O
eighteen	O
,	O
with	O
lesions	O
having	O
the	O
longest	O
axial	O
diameter	O
larger	O
than	O
15	O
mm	O
in	O
at	O
least	O
three	O
sections	O
,	O
were	O
considered	O
.	O

Lesions	O
whose	O
boundaries	O
could	O
not	O
be	O
accurately	O
identified	O
,	O
such	O
as	O
in	O
case	O
of	O
highly	O
inflamed	O
tissues	O
surrounding	O
the	O
tumour	B-DS
,	O
were	O
excluded	O
from	O
the	O
study	O
.	O

Finally	O
,	O
twelve	O
patients	O
(	O
nine	O
men	O
,	O
three	O
women	O
,	O
mean	O
age	O
64	O
.	O
7	O
years	O
,	O
range	O
42	O
–	O
81	O
years	O
)	O
with	O
a	O
target	O
lesion	O
having	O
mean	O
longest	O
axial	O
diameter	O
of	O
43	O
.	O
5	O
mm	O
(	O
range	O
25	O
.	O
3	O
–	O
75	O
.	O
2	O
mm	O
)	O
and	O
a	O
mean	O
area	O
of	O
1625	O
mm2	O
(	O
range	O
433	O
–	O
1995	O
mm2	O
)	O
were	O
enrolled	O
.	O

Five	O
of	O
them	O
underwent	O
at	O
least	O
one	O
FU	O
,	O
for	O
a	O
total	O
amount	O
of	O
26	O
CTp	O
examinations	O
.	O

2	O
.	O
1	O
.	O

CTp	O
Protocol	O
and	O
Perfusion	O
Maps	O

Axial	O
CTp	O
examinations	O
were	O
carried	O
out	O
using	O
a	O
256	O
-	O
slice	O
CT	O
system	O
(	O
Brilliance	O
iCT	O
,	O
Philips	O
Medical	O
Systems	O
,	O
Best	O
,	O
The	O
Netherlands	O
).	O

Patients	O
were	O
instructed	O
for	O
breath	O
-	O
hold	O
and	O
laid	O
in	O
the	O
supine	O
(	O
feet	O
first	O
)	O
position	O
.	O

An	O
initial	O
full	O
-	O
body	O
,	O
unenhanced	O
and	O
low	O
-	O
dose	O
,	O
CT	O
scan	O
was	O
performed	O
to	O
identify	O
the	O
target	O
lesion	O
at	O
the	O
baseline	O
condition	O
.	O

Then	O
,	O
50	O
mL	O
of	O
intravenous	O
bolus	O
of	O
contrast	O
agent	O
(	O
Iomeron	O
,	O
Bracco	O
,	O
Milan	O
,	O
Italy	O
)	O
was	O
administered	O
to	O
the	O
patients	O
at	O
5	O
mL	O
/	O
s	O
.	O

Five	O
seconds	O
later	O
,	O
a	O
CTp	O
scan	O
of	O
25	O
-	O
second	O
duration	O
was	O
performed	O
at	O
fixed	O
tube	O
voltage	O
(	O
80	O
kV	O
),	O
current	O
(	O
250	O
mA	O
),	O
and	O
exposure	O
(	O
100	O
mAs	O
).	O

The	O
protocol	O
yielded	O
20	O
scans	O
,	O
centred	O
on	O
the	O
target	O
lesion	O
,	O
with	O
a	O
z	O
-	O
coverage	O
of	O
55	O
mm	O
(	O
11	O
slices	O
×	O
5	O
mm	O
thickness	O
,	O
0	O
.	O
4	O
-	O
second	O
rotation	O
time	O
),	O
and	O
rearranged	O
into	O
220	O
cine	O
images	O
(	O
512	O
×	O
512	O
pixel	O
,	O
350	O
mm	O
×	O
350	O
mm	O
,	O
5	O
mm	O
slice	O
spacing	O
,	O
and	O
1	O
.	O
25	O
-	O
second	O
temporal	O
resolution	O
).	O

For	O
each	O
slice	O
,	O
the	O
longest	O
axial	O
diameter	O
was	O
computed	O
,	O
using	O
a	O
digital	O
calliper	O
.	O

Due	O
to	O
the	O
inclusion	O
criteria	O
,	O
the	O
number	O
of	O
slices	O
where	O
tumours	B-DS
are	O
visible	O
changes	O
for	O
each	O
examination	O
,	O
but	O
they	O
are	O
almost	O
always	O
visible	O
for	O
at	O
least	O
five	O
slices	O
.	O

For	O
this	O
reason	O
,	O
the	O
set	O
of	O
the	O
five	O
central	O
slices	O
was	O
selected	O
[	O
27	O
],	O
achieving	O
118	O
slices	O
(	O
57	O
for	O
baseline	O
CTp	O
and	O
61	O
for	O
FUs	O
)	O
altogether	O
.	O

Hereinafter	O
,	O
the	O
set	O
of	O
slices	O
of	O
each	O
tumour	B-DS
is	O
referred	O
to	O
as	O
the	O
“	O
whole	O
tumour	B-DS
.”	O

Two	O
25	O
-	O
year	O
experienced	O
radiologists	O
analysed	O
the	O
whole	O
sequences	O
in	O
cine	O
-	O
mode	O
fashion	O
and	O
in	O
agreement	O
,	O
for	O
each	O
examination	O
,	O
placed	O
a	O
circular	O
region	O
of	O
interest	O
(	O
ROI	O
)	O
within	O
the	O
aorta	O
to	O
extract	O
the	O
arterial	O
input	O
and	O
,	O
for	O
each	O
slice	O
,	O
drew	O
a	O
ROI	O
following	O
the	O
margin	O
of	O
tumours	B-DS
.	O

Voxel	O
-	O
based	O
BF	O
values	O
,	O
expressed	O
in	O
mL	O
/	O
min	O
/	O
100	O
g	O
,	O
were	O
computed	O
for	O
each	O
slice	O
,	O
using	O
an	O
in	O
-	O
house	O
algorithm	O
developed	O
in	O
Matlab	O
(	O
MathWorks	O
,	O
Natick	O
,	O
MA	O
),	O
implementing	O
the	O
maximum	O
slope	O
method	O
[	O
35	O
]	O
and	O
represented	O
through	O
the	O
use	O
of	O
colorimetric	O
maps	O
.	O

Misleading	O
perfusion	O
values	O
computed	O
on	O
poorly	O
representative	O
TCCs	O
(	O
due	O
to	O
a	O
bad	O
fit	O
)	O
were	O
excluded	O
from	O
the	O
analysis	O
according	O
to	O
what	O
is	O
reported	O
in	O
[	O
16	O
,	O
36	O
],	O
in	O
order	O
to	O
obtain	O
more	O
reliable	O
results	O
.	O

The	O
corresponding	O
voxels	O
are	O
displayed	O
in	O
the	O
colour	O
maps	O
with	O
the	O
“	O
pink	O
”	O
colour	O
.	O

Mean	O
BF	O
values	O
representative	O
of	O
each	O
slice	O
(	O
μs	O
)	O
and	O
of	O
the	O
whole	O
lesion	O
(	O
μw	O
)	O
were	O
computed	O
for	O
each	O
examination	O
.	O

Median	O
values	O
were	O
also	O
computed	O
for	O
each	O
slice	O
(	O
Ms	O
)	O
and	O
the	O
whole	O
lesion	O
(	O
Mw	O
).	O

The	O
ranges	O
(	O
r	O
)	O
between	O
minimum	O
and	O
maximum	O
of	O
μs	O
and	O
Ms	O
,	O
rμ	O
and	O
rM	O
,	O
respectively	O
,	O
were	O
computed	O
as	O
a	O
variability	O
measure	O
referred	O
to	O
as	O
the	O
whole	O
volume	O
.	O

2	O
.	O
2	O
.	O

Heterogeneity	O
Analysis	O
of	O
BF	O
Maps	O

The	O
entropy	O
is	O
a	O
measure	O
often	O
used	O
in	O
texture	O
analysis	O
,	O
also	O
applied	O
to	O
the	O
oncologic	O
field	O
,	O
for	O
instance	O
,	O
to	O
get	O
a	O
measure	O
of	O
texture	O
irregularities	O
[	O
12	O
].	O

Besides	O
that	O
,	O
the	O
entropy	O
,	O
computed	O
on	O
both	O
nonenhanced	O
and	O
contrast	O
-	O
enhanced	O
CT	O
images	O
,	O
has	O
been	O
shown	O
to	O
correlate	O
with	O
the	O
overall	O
survival	O
in	O
patients	O
with	O
colorectal	B-DS
cancer	I-DS
[	O
37	O
]	O
and	O
gliomas	B-DS
[	O
38	O
]	O
and	O
with	O
tumour	B-DS
staging	O
[	O
39	O
]	O
and	O
overall	O
survival	O
[	O
24	O
]	O
in	O
patients	O
with	O
NSCLC	B-DS
.	O

In	O
this	O
work	O
,	O
the	O
entropy	O
,	O
E	O
,	O
was	O
computed	O
for	O
the	O
first	O
time	O
on	O
the	O
BF	O
maps	O
of	O
the	O
whole	O
tumour	B-DS
(	O
Ew	O
)	O
and	O
of	O
each	O
slice	O
(	O
Es	O
),	O
with	O
the	O
purpose	O
to	O
get	O
a	O
measure	O
of	O
the	O
hemodynamic	O
heterogeneity	O
.	O

The	O
range	O
rE	O
between	O
minimum	O
and	O
maximum	O
Ew	O
values	O
is	O
also	O
considered	O
as	O
a	O
measure	O
of	O
the	O
heterogeneity	O
variability	O
in	O
the	O
whole	O
tumour	B-DS
.	O
E	O
measures	O
are	O
reported	O
in	O
arbitrary	O
units	O
(	O
a	O
.	O
u	O
.).	O

More	O
details	O
are	O
given	O
in	O
the	O
Appendix	O
.	O

Figure	O
1	O
reports	O
an	O
example	O
of	O
BF	O
maps	O
,	O
referred	O
to	O
as	O
lesion	O
ID8	O
,	O
ordered	O
from	O
(	O
a	O
)	O
to	O
(	O
e	O
)	O
according	O
to	O
increasing	O
Es	O
values	O
.	O

2	O
.	O
3	O
.	O

Statistical	O
and	O
Data	O
Analysis	O

Statistical	O
analysis	O
was	O
performed	O
by	O
using	O
statistical	O
software	O
(	O
R	O
,	O
version	O
3	O
.	O
2	O
.	O
1	O
,	O
The	O
R	O
Foundation	O
for	O
Statistical	O
Computing	O
).	O
p	O
values	O
≤	O
0	O
.	O
05	O
were	O
considered	O
for	O
statistical	O
significance	O
.	O

Kendall	O
-	O
τ	O
coefficient	O
was	O
used	O
to	O
assess	O
any	O
possible	O
correlation	O
between	O
measurement	O
errors	O
and	O
their	O
magnitude	O
:	O
in	O
case	O
of	O
concordance	O
,	O
data	O
were	O
log	O
-	O
transformed	O
.	O

Three	O
groups	O
of	O
statistical	O
tests	O
were	O
performed	O
.	O

First	O
,	O
the	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
was	O
performed	O
to	O
check	O
whether	O
all	O
slices	O
(	O
the	O
“	O
groups	O
”)	O
of	O
the	O
same	O
tumour	B-DS
have	O
the	O
same	O
mean	O
value	O
,	O
that	O
is	O
,	O
whether	O
they	O
can	O
represent	O
the	O
same	O
population	O
,	O
in	O
terms	O
of	O
BF	O
values	O
.	O

An	O
analogous	O
assessment	O
was	O
carried	O
out	O
for	O
medians	O
,	O
through	O
the	O
Chi	O
-	O
squared	O
test	O
of	O
independence	O
.	O

The	O
second	O
group	O
consists	O
in	O
the	O
two	O
-	O
tail	O
t	O
-	O
test	O
and	O
the	O
Wilcoxon	O
rank	O
sum	O
test	O
,	O
which	O
were	O
utilized	O
for	O
three	O
different	O
purposes	O
.	O

In	O
fact	O
,	O
they	O
were	O
applied	O
to	O
test	O
,	O
for	O
each	O
lesion	O
,	O
the	O
difference	O
of	O
means	O
and	O
medians	O
,	O
respectively	O
,	O
between	O
each	O
slice	O
and	O
the	O
whole	O
tumour	B-DS
,	O
with	O
the	O
purpose	O
to	O
check	O
whether	O
a	O
slice	O
exists	O
which	O
can	O
represent	O
the	O
whole	O
tumour	B-DS
(	O
i	O
.	O
e	O
.,	O
having	O
the	O
same	O
global	O
value	O
).	O

The	O
same	O
tests	O
were	O
also	O
carried	O
out	O
to	O
check	O
for	O
μs	O
or	O
Ms	O
differences	O
between	O
couples	O
of	O
slices	O
,	O
whether	O
they	O
belonged	O
to	O
same	O
tumour	B-DS
or	O
different	O
ones	O
.	O

Finally	O
,	O
they	O
were	O
employed	O
to	O
select	O
which	O
tumours	B-DS
have	O
the	O
same	O
statistical	O
μw	O
or	O
Mw	O
values	O
,	O
to	O
further	O
compare	O
their	O
perfusion	O
patterns	O
(	O
i	O
.	O
e	O
.,	O
their	O
Ew	O
).	O

In	O
fact	O
,	O
computing	O
and	O
using	O
a	O
global	O
mean	O
,	O
or	O
median	O
,	O
perfusion	O
value	O
for	O
CTp	O
studies	O
implicitly	O
means	O
that	O
sets	O
of	O
BF	O
values	O
(	O
e	O
.	O
g	O
.,	O
slices	O
or	O
whole	O
tumours	B-DS
)	O
with	O
same	O
μs	O
(	O
or	O
Ms	O
)	O
as	O
μw	O
(	O
or	O
Mw	O
)	O
are	O
clinically	O
equivalent	O
.	O

The	O
third	O
group	O
of	O
tests	O
is	O
composed	O
by	O
the	O
one	O
-	O
tail	O
t	O
-	O
test	O
only	O
,	O
which	O
was	O
performed	O
to	O
assess	O
the	O
differences	O
between	O
the	O
means	O
of	O
Es	O
for	O
baseline	O
and	O
FU	O
examinations	O
.	O

3	O
.	O

Results	O

The	O
goal	O
of	O
this	O
section	O
is	O
assessing	O
the	O
capability	O
of	O
global	O
values	O
,	O
computed	O
on	O
the	O
whole	O
tumour	B-DS
,	O
to	O
represent	O
the	O
clinically	O
relevant	O
perfusion	O
features	O
of	O
a	O
tumour	B-DS
,	O
assuming	O
that	O
the	O
heterogeneity	O
is	O
among	O
the	O
most	O
important	O
ones	O
[	O
40	O
].	O

To	O
this	O
purpose	O
,	O
we	O
addressed	O
tumours	B-DS
with	O
different	O
heterogeneities	O
,	O
referring	O
to	O
baseline	O
and	O
FUs	O
examinations	O
,	O
by	O
comparing	O
those	O
with	O
the	O
same	O
global	O
value	O
.	O

In	O
addition	O
,	O
whole	O
tumours	B-DS
and	O
their	O
composing	O
slices	O
with	O
same	O
global	O
values	O
were	O
compared	O
as	O
well	O
.	O

In	O
this	O
section	O
,	O
we	O
aim	O
to	O
check	O
whether	O
,	O
and	O
to	O
what	O
extent	O
,	O
numerical	O
equivalence	O
matches	O
with	O
clinical	O
one	O
.	O

As	O
the	O
first	O
outcome	O
,	O
it	O
is	O
worth	O
reporting	O
that	O
the	O
hypotheses	O
that	O
means	O
or	O
medians	O
of	O
slices	O
were	O
all	O
equivalent	O
were	O
rejected	O
,	O
for	O
each	O
examination	O
.	O

Actually	O
,	O
this	O
finding	O
was	O
expected	O
and	O
suggests	O
that	O
the	O
variability	O
between	O
slices	O
is	O
significantly	O
greater	O
than	O
the	O
variability	O
within	O
slices	O
[	O
41	O
].	O

Tables	O
1	O
and	O
2	O
report	O
the	O
most	O
significant	O
measures	O
(	O
entropy	O
,	O
mean	O
,	O
and	O
median	O
)	O
for	O
all	O
examinations	O
,	O
calculated	O
on	O
BF	O
values	O
of	O
each	O
slice	O
and	O
of	O
the	O
whole	O
tumour	B-DS
.	O

The	O
range	O
of	O
measures	O
is	O
also	O
reported	O
.	O

For	O
the	O
sake	O
of	O
brevity	O
,	O
in	O
this	O
section	O
we	O
just	O
report	O
a	O
subset	O
of	O
the	O
most	O
interesting	O
cases	O
.	O

3	O
.	O
1	O
.	O

Baseline	O
CTp	O

Table	O
1	O
resumes	O
the	O
most	O
significant	O
measures	O
for	O
the	O
baseline	O
CTp	O
examinations	O
.	O

Statistical	O
analysis	O
shows	O
that	O
ten	O
slices	O
exist	O
which	O
have	O
the	O
same	O
global	O
BF	O
as	O
the	O
respective	O
whole	O
tumour	B-DS
,	O
seven	O
times	O
regarding	O
mean	O
values	O
,	O
and	O
eight	O
ones	O
median	O
values	O
.	O

Five	O
times	O
the	O
whole	O
tumour	B-DS
could	O
be	O
represented	O
by	O
the	O
same	O
slice	O
detected	O
by	O
both	O
μw	O
and	O
Mw	O
values	O
.	O
μw	O
and	O
Mw	O
values	O
never	O
selected	O
the	O
slice	O
with	O
maximum	O
Es	O
and	O
one	O
time	O
selected	O
the	O
slice	O
with	O
minimum	O
Es	O
(	O
ID12	O
and	O
ID4	O
,	O
for	O
mean	O
and	O
median	O
,	O
respectively	O
).	O
Figure	O
2	O
reports	O
the	O
five	O
slices	O
of	O
ID12	O
,	O
one	O
of	O
the	O
most	O
interesting	O
lesions	O
,	O
where	O
the	O
average	O
BF	O
value	O
of	O
the	O
whole	O
tumour	B-DS
(	O
μw	O
=	O
125	O
.	O
0	O
)	O
corresponds	O
to	O
that	O
of	O
the	O
first	O
slice	O
(	O
μs	O
=	O
124	O
.	O
5	O
,	O
Figure	O
2	O
(	O
a	O
),	O
last	O
row	O
).	O

It	O
is	O
worth	O
noting	O
that	O
this	O
slice	O
also	O
retains	O
the	O
minimum	O
Es	O
=	O
7	O
.	O
48	O
,	O
that	O
is	O
,	O
the	O
lowest	O
heterogeneity	O
.	O

In	O
fact	O
,	O
it	O
shows	O
quite	O
a	O
uniform	O
,	O
low	O
,	O
perfusion	O
.	O

On	O
the	O
contrary	O
,	O
the	O
last	O
slice	O
(	O
Figure	O
2	O
(	O
e	O
))	O
shows	O
a	O
marked	O
heterogeneity	O
,	O
the	O
highest	O
one	O
(	O
Es	O
=	O
8	O
.	O
37	O
),	O
having	O
in	O
its	O
upper	O
part	O
a	O
hyperperfused	O
region	O
(	O
with	O
BF	O
values	O
higher	O
than	O
300	O
),	O
and	O
a	O
lower	O
hypoperfused	O
region	O
with	O
BF	O
values	O
nearly	O
40	O
.	O

3	O
.	O
2	O
.	O

Follow	O
-	O
Ups	O
CTp	O

Table	O
2	O
resumes	O
the	O
most	O
significant	O
measures	O
for	O
the	O
FU	O
CTp	O
examinations	O
.	O

Fifteen	O
slices	O
were	O
representative	O
of	O
the	O
whole	O
tumour	B-DS
,	O
thirteen	O
of	O
which	O
regarding	O
mean	O
BF	O
values	O
,	O
and	O
eight	O
pertaining	O
to	O
median	O
values	O
.	O

Five	O
times	O
,	O
mean	O
and	O
median	O
global	O
BF	O
values	O
identified	O
the	O
same	O
slice	O
.	O

For	O
lesions	O
ID6	O
-	O
FU3	O
(	O
Figure	O
3	O
,	O
μw	O
=	O
44	O
.	O
4	O
and	O
Mw	O
=	O
37	O
.	O
8	O
)	O
and	O
ID6	O
-	O
FU4	O
(	O
Figure	O
4	O
,	O
μw	O
=	O
39	O
.	O
2	O
and	O
Mw	O
=	O
33	O
.	O
2	O
),	O
the	O
same	O
slices	O
(	O
i	O
.	O
e	O
.,	O
slice	O
3	O
for	O
both	O
)	O
were	O
those	O
with	O
maximum	O
E	O
(	O
Es	O
=	O
6	O
.	O
73	O
and	O
Es	O
=	O
6	O
.	O
49	O
,	O
respectively	O
),	O
probably	O
due	O
to	O
these	O
examinations	O
being	O
subsequent	O
FUs	O
of	O
the	O
same	O
lesion	O
.	O

In	O
addition	O
,	O
this	O
is	O
the	O
only	O
ID	O
where	O
mean	O
and	O
median	O
select	O
the	O
highest	O
E	O
.	O

As	O
regards	O
ID6	O
-	O
FU4	O
,	O
it	O
shows	O
limited	O
BF	O
ranges	O
(	O
rμ	O
=	O
7	O
.	O
3	O
and	O
rM	O
=	O
8	O
.	O
0	O
,	O
among	O
the	O
lowest	O
values	O
of	O
all	O
examinations	O
)	O
and	O
μs	O
and	O
Ms	O
are	O
substantially	O
equivalent	O
for	O
the	O
three	O
central	O
slices	O
.	O

This	O
consideration	O
regarding	O
mean	O
range	O
also	O
holds	O
for	O
ID6	O
-	O
FU3	O
,	O
where	O
rμ	O
=	O
13	O
.	O
8	O
is	O
a	O
little	O
higher	O
,	O
but	O
still	O
among	O
the	O
lowest	O
ones	O
.	O

As	O
for	O
median	O
,	O
in	O
ID6	O
-	O
FU3	O
it	O
also	O
selects	O
slice	O
2	O
(	O
Ms	O
=	O
36	O
.	O
9	O
)	O
that	O
has	O
the	O
lowest	O
Es	O
=	O
6	O
.	O
26	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
ID11	O
-	O
FU4	O
(	O
Figure	O
5	O
),	O
Mw	O
=	O
63	O
.	O
3	O
selects	O
slice	O
1	O
(	O
Ms	O
=	O
64	O
.	O
3	O
)	O
which	O
is	O
the	O
one	O
with	O
the	O
lowest	O
Es	O
=	O
7	O
.	O
05	O
.	O

3	O
.	O
3	O
.	O

Baseline	O
and	O
FU	O
CTp	O

In	O
this	O
section	O
,	O
we	O
extend	O
the	O
analysis	O
over	O
the	O
whole	O
dataset	O
,	O
by	O
considering	O
all	O
the	O
CTp	O
examinations	O
together	O
.	O

As	O
regards	O
the	O
whole	O
sets	O
of	O
slices	O
,	O
the	O
most	O
meaningful	O
result	O
is	O
that	O
on	O
the	O
whole	O
93	O
slices	O
were	O
not	O
represented	O
by	O
the	O
global	O
BF	O
values	O
computed	O
on	O
the	O
whole	O
tumour	B-DS
.	O

As	O
for	O
the	O
sets	O
of	O
whole	O
tumours	B-DS
,	O
here	O
we	O
analyse	O
the	O
sets	O
of	O
slices	O
referring	O
to	O
two	O
couples	O
of	O
meaningful	O
lesions	O
.	O
Figure	O
6	O
shows	O
the	O
BF	O
maps	O
of	O
the	O
four	O
consecutive	O
slices	O
(	O
1	O
–	O
4	O
,	O
from	O
(	O
a	O
)	O
to	O
(	O
d	O
))	O
of	O
ID11	O
(	O
μw	O
=	O
80	O
.	O
0	O
,	O
first	O
row	O
)	O
and	O
ID6	O
-	O
FU1	O
(	O
μw	O
=	O
77	O
.	O
5	O
,	O
second	O
row	O
).	O

Although	O
these	O
lesions	O
have	O
statistically	O
equivalent	O
μw	O
,	O
the	O
respective	O
composing	O
slices	O
have	O
a	O
different	O
heterogeneity	O
distribution	O
.	O

In	O
fact	O
,	O
the	O
heterogeneity	O
in	O
all	O
slices	O
(	O
except	O
for	O
slice	O
3	O
)	O
of	O
ID11	O
is	O
quite	O
comparable	O
,	O
as	O
it	O
can	O
be	O
seen	O
from	O
Es	O
values	O
of	O
Table	O
1	O
.	O

On	O
the	O
contrary	O
,	O
slices	O
1	O
and	O
2	O
of	O
ID6	O
-	O
FU1	O
(	O
Figures	O
6	O
(	O
a	O
)	O
and	O
6	O
(	O
b	O
),	O
second	O
row	O
)	O
are	O
quite	O
homogeneous	O
and	O
low	O
-	O
perfused	O
,	O
while	O
slice	O
4	O
(	O
Figure	O
6	O
(	O
d	O
),	O
second	O
row	O
)	O
has	O
the	O
highest	O
μs	O
=	O
150	O
.	O
8	O
and	O
Es	O
=	O
7	O
.	O
75	O
.	O

In	O
addition	O
,	O
here	O
the	O
heterogeneity	O
is	O
made	O
of	O
local	O
homogeneities	O
,	O
with	O
a	O
hyperperfused	O
upper	O
region	O
and	O
a	O
hypoperfusion	O
in	O
the	O
lower	O
one	O
.	O

Similar	O
comments	O
can	O
be	O
done	O
for	O
ID3	O
and	O
ID2	O
-	O
FU1	O
,	O
made	O
of	O
five	O
slices	O
each	O
,	O
whose	O
BF	O
maps	O
are	O
shown	O
in	O
Figure	O
7	O
,	O
first	O
and	O
second	O
row	O
,	O
respectively	O
.	O

ID3	O
(	O
μw	O
=	O
111	O
.	O
8	O
)	O
shows	O
a	O
heterogeneity	O
that	O
keeps	O
quite	O
“	O
homogeneous	O
”	O
within	O
all	O
slices	O
(	O
rE	O
=	O
0	O
.	O
23	O
,	O
the	O
second	O
lowest	O
value	O
),	O
also	O
in	O
terms	O
of	O
mean	O
(	O
rμ	O
=	O
15	O
.	O
2	O
)	O
and	O
median	O
(	O
rM	O
=	O
10	O
.	O
2	O
)	O
BF	O
(	O
among	O
the	O
lowest	O
values	O
),	O
with	O
all	O
μs	O
around	O
μw	O
=	O
111	O
.	O
8	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
heterogeneity	O
in	O
ID2	O
-	O
FU1	O
(	O
μw	O
=	O
112	O
.	O
8	O
)	O
is	O
made	O
of	O
well	O
-	O
defined	O
hyper	O
-	O
and	O
hypoperfused	O
regions	O
,	O
mostly	O
evident	O
in	O
the	O
upper	O
and	O
lower	O
part	O
,	O
respectively	O
,	O
of	O
slices	O
2	O
and	O
3	O
.	O

Finally	O
,	O
we	O
also	O
analysed	O
the	O
distribution	O
of	O
all	O
slice	O
entropies	O
Es	O
for	O
baseline	O
and	O
FU	O
examinations	O
,	O
separately	O
.	O

Related	O
histograms	O
are	O
reported	O
in	O
Figures	O
8	O
(	O
a	O
)	O
and	O
8	O
(	O
b	O
),	O
respectively	O
.	O

Even	O
at	O
a	O
glance	O
,	O
the	O
histograms	O
of	O
baseline	O
examinations	O
appear	O
shifted	O
right	O
with	O
respect	O
to	O
the	O
FU	O
ones	O
.	O

In	O
fact	O
,	O
for	O
baselines	O
mean	O
and	O
standard	O
deviation	O
are	O
7	O
.	O
4	O
and	O
0	O
.	O
75	O
,	O
respectively	O
,	O
while	O
for	O
FUs	O
they	O
are	O
6	O
.	O
9	O
and	O
0	O
.	O
64	O
.	O

Statistical	O
tests	O
confirm	O
that	O
the	O
mean	O
entropy	O
of	O
all	O
slices	O
is	O
greater	O
for	O
baseline	O
examinations	O
(	O
p	O
values	O
≤	O
10	O
−	O
4	O
).	O

4	O
.	O

Discussion	O

Quantitative	O
imaging	O
has	O
gained	O
an	O
increasing	O
interest	O
in	O
these	O
last	O
years	O
,	O
as	O
the	O
need	O
of	O
personalized	O
therapies	O
progresses	O
[	O
42	O
],	O
deepening	O
the	O
knowledge	O
of	O
tumour	B-DS
'	O
s	O
heterogeneity	O
,	O
the	O
most	O
important	O
intrinsic	O
properties	O
of	O
tumours	B-DS
.	O

In	O
particular	O
,	O
perfusion	O
'	O
s	O
heterogeneity	O
is	O
from	O
decades	O
a	O
well	O
-	O
known	O
characteristic	O
of	O
many	O
tumours	B-DS
[	O
40	O
].	O

However	O
,	O
functional	O
results	O
obtained	O
from	O
CTp	O
are	O
still	O
analysed	O
using	O
global	O
statistical	O
indexes	O
,	O
such	O
as	O
mean	O
or	O
median	O
operators	O
,	O
that	O
many	O
times	O
permit	O
measurement	O
reproducibility	O
,	O
while	O
disregarding	O
tumour	B-DS
heterogeneity	O
[	O
43	O
].	O

Together	O
with	O
the	O
uncertainty	O
on	O
reliability	O
of	O
voxel	O
-	O
based	O
perfusion	O
measurements	O
,	O
this	O
represents	O
one	O
of	O
the	O
most	O
relevant	O
causes	O
preventing	O
the	O
diffusion	O
of	O
CTp	O
in	O
clinical	O
oncology	O
,	O
mainly	O
to	O
assess	O
the	O
outcome	O
of	O
therapies	O
,	O
such	O
as	O
antiangiogenic	O
treatments	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
deeply	O
analysed	O
the	O
representativeness	O
of	O
global	O
mean	O
and	O
median	O
values	O
,	O
as	O
far	O
as	O
the	O
heterogeneity	O
is	O
concerned	O
,	O
starting	O
from	O
the	O
assumption	O
that	O
computing	O
and	O
using	O
a	O
global	O
mean	O
,	O
or	O
median	O
,	O
perfusion	O
value	O
for	O
clinical	O
purposes	O
means	O
accepting	O
that	O
the	O
characteristics	O
of	O
the	O
tumour	B-DS
are	O
represented	O
by	O
that	O
value	O
alone	O
.	O

Accordingly	O
,	O
this	O
implies	O
that	O
sets	O
of	O
BF	O
values	O
(	O
e	O
.	O
g	O
.,	O
slices	O
or	O
whole	O
tumours	B-DS
),	O
with	O
statistically	O
equivalent	O
mean	O
or	O
median	O
values	O
,	O
are	O
equivalently	O
representative	O
.	O

The	O
outcome	O
of	O
this	O
work	O
proves	O
that	O
these	O
are	O
numerical	O
equivalences	O
only	O
,	O
not	O
clinical	O
ones	O
.	O

In	O
fact	O
,	O
we	O
have	O
discussed	O
lesions	O
with	O
same	O
global	O
mean	O
or	O
median	O
BF	O
values	O
,	O
which	O
showed	O
a	O
very	O
different	O
heterogeneity	O
.	O

In	O
addition	O
,	O
we	O
analysed	O
tumour	B-DS
slices	O
having	O
the	O
same	O
global	O
values	O
as	O
the	O
whole	O
tumour	B-DS
and	O
we	O
realized	O
that	O
,	O
when	O
those	O
slices	O
existed	O
,	O
for	O
baseline	O
examinations	O
they	O
were	O
never	O
those	O
with	O
the	O
highest	O
information	O
content	O
.	O

Rather	O
,	O
it	O
happened	O
that	O
in	O
two	O
examinations	O
the	O
whole	O
tumour	B-DS
had	O
mean	O
and	O
median	O
BF	O
values	O
corresponding	O
to	O
the	O
slice	O
with	O
the	O
lowest	O
heterogeneity	O
(	O
ID12	O
and	O
ID4	O
,	O
respectively	O
),	O
while	O
the	O
remaining	O
slices	O
showed	O
relevant	O
clinical	O
signs	O
of	O
different	O
heterogeneities	O
.	O

For	O
FU	O
examinations	O
,	O
there	O
was	O
only	O
the	O
wide	O
,	O
and	O
highly	O
necrotic	O
,	O
uniform	O
lesion	O
ID6	O
where	O
mean	O
and	O
median	O
selected	O
the	O
region	O
with	O
the	O
highest	O
E	O
,	O
in	O
two	O
subsequent	O
FU	O
examinations	O
.	O

In	O
addition	O
,	O
results	O
prove	O
that	O
using	O
the	O
median	O
as	O
a	O
more	O
robust	O
estimator	O
is	O
not	O
so	O
effective	O
as	O
expected	O
,	O
since	O
mean	O
and	O
median	O
practically	O
select	O
the	O
same	O
slices	O
.	O

Rather	O
,	O
in	O
ID6	O
-	O
FU3	O
,	O
the	O
median	O
operator	O
selects	O
the	O
slices	O
with	O
maximum	O
and	O
minimum	O
Es	O
,	O
at	O
the	O
same	O
time	O
.	O

This	O
behaviour	O
has	O
relevantly	O
misleading	O
properties	O
,	O
all	O
the	O
more	O
so	O
because	O
median	O
is	O
considered	O
a	O
powerful	O
outlier	O
removal	O
.	O

Actually	O
,	O
this	O
is	O
true	O
,	O
if	O
erroneous	O
values	O
lay	O
in	O
the	O
extreme	O
of	O
values	O
domain	O
,	O
but	O
median	O
cannot	O
work	O
in	O
case	O
that	O
discriminating	O
BF	O
outliers	O
strongly	O
depends	O
on	O
spatial	O
displacement	O
and	O
arrangement	O
of	O
BF	O
values	O
themselves	O
.	O

5	O
.	O

Conclusion	O

Global	O
perfusion	O
values	O
computed	O
on	O
the	O
whole	O
tumour	B-DS
cannot	O
be	O
appropriate	O
for	O
therapy	O
assessment	O
and	O
cannot	O
improve	O
the	O
reproducibility	O
of	O
heterogeneity	O
,	O
accordingly	O
.	O

In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
the	O
global	O
values	O
computed	O
on	O
the	O
whole	O
tumour	B-DS
have	O
a	O
correspondence	O
with	O
parts	O
of	O
tumour	B-DS
(	O
i	O
.	O
e	O
.,	O
slices	O
)	O
that	O
,	O
just	O
occasionally	O
,	O
could	O
have	O
either	O
maximum	O
or	O
minimum	O
entropy	O
.	O

In	O
the	O
remaining	O
cases	O
,	O
they	O
have	O
not	O
any	O
correspondence	O
with	O
any	O
real	O
parts	O
of	O
the	O
tumour	B-DS
and	O
just	O
represent	O
a	O
generic	O
tumour	B-DS
BF	O
averaged	O
behaviour	O
,	O
which	O
is	O
far	O
from	O
representing	O
its	O
real	O
clinical	O
features	O
.	O

And	O
perhaps	O
,	O
this	O
happens	O
much	O
more	O
times	O
than	O
expected	O
.	O

As	O
far	O
as	O
single	O
slices	O
are	O
concerned	O
,	O
although	O
preserving	O
more	O
details	O
,	O
they	O
may	O
be	O
not	O
representative	O
of	O
the	O
clinical	O
status	O
of	O
the	O
whole	O
lesion	O
and	O
this	O
could	O
severely	O
mislead	O
clinical	O
considerations	O
.	O

The	O
solution	O
is	O
not	O
at	O
hand	O
,	O
but	O
the	O
research	O
carried	O
out	O
in	O
this	O
work	O
suggests	O
that	O
the	O
first	O
step	O
is	O
being	O
very	O
prudent	O
in	O
considering	O
the	O
global	O
(	O
mean	O
or	O
median	O
)	O
BF	O
values	O
as	O
useful	O
indicators	O
for	O
therapy	O
assessment	O
.	O

On	O
the	O
other	O
hand	O
,	O
measuring	O
heterogeneity	O
is	O
a	O
key	O
issue	O
to	O
achieve	O
useful	O
information	O
to	O
assess	O
the	O
effectiveness	O
of	O
antiangiogenic	O
therapies	O
that	O
cannot	O
be	O
left	O
out	O
of	O
consideration	O
.	O

This	O
is	O
confirmed	O
by	O
the	O
comparison	O
between	O
the	O
average	O
BF	O
entropy	O
of	O
all	O
slices	O
before	O
(	O
baseline	O
)	O
and	O
after	O
(	O
FU	O
)	O
treatment	O
,	O
proving	O
the	O
effectiveness	O
of	O
treatments	O
themselves	O
,	O
expectedly	O
reducing	O
the	O
overall	O
BF	O
heterogeneity	O
of	O
tumours	B-DS
.	O

We	O
have	O
also	O
seen	O
that	O
the	O
single	O
slices	O
of	O
a	O
tumour	B-DS
are	O
widely	O
varying	O
from	O
each	O
other	O
and	O
can	O
represent	O
different	O
BF	O
heterogeneity	O
patterns	O
that	O
,	O
on	O
the	O
whole	O
,	O
could	O
provide	O
a	O
radiologist	O
with	O
an	O
overall	O
view	O
of	O
the	O
whole	O
tumour	B-DS
.	O

Indeed	O
,	O
using	O
all	O
the	O
single	O
slices	O
of	O
a	O
tumour	B-DS
,	O
endowed	O
with	O
global	O
BF	O
values	O
and	O
a	O
BF	O
heterogeneity	O
measures	O
,	O
would	O
represent	O
a	O
step	O
forwards	O
,	O
useful	O
to	O
help	O
radiologists	O
to	O
draw	O
more	O
reliable	O
clinical	O
considerations	O
.	O

As	O
concluding	O
notes	O
,	O
we	O
believe	O
that	O
improving	O
the	O
reliability	O
of	O
voxel	O
-	O
based	O
perfusion	O
values	O
has	O
to	O
be	O
coupled	O
with	O
the	O
reproducibility	O
assessment	O
of	O
heterogeneity	O
measurements	O
.	O

To	O
this	O
purpose	O
,	O
a	O
deeper	O
application	O
of	O
the	O
bioengineering	O
and	O
computer	O
science	O
techniques	O
to	O
CTp	O
data	O
processing	O
,	O
in	O
a	O
multidisciplinary	O
team	O
,	O
will	O
play	O
a	O
key	O
role	O
in	O
the	O
next	O
future	O
to	O
help	O
translation	O
of	O
CTp	O
into	O
clinics	O
.	O

The	O
achievements	O
of	O
this	O
work	O
could	O
be	O
also	O
assessed	O
using	O
other	O
perfusion	O
parameters	O
,	O
such	O
as	O
the	O
blood	O
volume	O
and	O
the	O
mean	O
transit	O
time	O
.	O

In	O
addition	O
,	O
a	O
study	O
dedicated	O
to	O
validate	O
the	O
BF	O
entropy	O
as	O
a	O
surrogate	O
biomarker	O
for	O
the	O
overall	O
survival	O
is	O
being	O
carried	O
out	O
,	O
based	O
on	O
the	O
existing	O
correlation	O
between	O
BF	O
entropy	O
and	O
tumour	B-DS
grading	O
.	O

Original	O
ROIs	O
(	O
HU	O
,	O
first	O
row	O
)	O
and	O
BF	O
maps	O
(	O
second	O
row	O
)	O
of	O
all	O
adjacent	O
slices	O
of	O
lesion	O
ID8	O
,	O
ordered	O
by	O
increasing	O
Es	O
values	O
:	O
the	O
slice	O
at	O
level	O
2	O
(	O
Es	O
=	O
7	O
.	O
07	O
)	O
(	O
a	O
),	O
level	O
1	O
(	O
Es	O
=	O
7	O
.	O
43	O
)	O
(	O
b	O
),	O
level	O
5	O
(	O
Es	O
=	O
7	O
.	O
62	O
)	O
(	O
c	O
),	O
level	O
4	O
(	O
Es	O
=	O
7	O
.	O
92	O
)	O
(	O
d	O
),	O
and	O
level	O
3	O
(	O
Es	O
=	O
8	O
.	O
10	O
)	O
(	O
e	O
).	O

Values	O
are	O
reported	O
in	O
arbitrary	O
units	O
(	O
a	O
.	O
u	O
.).	O

ID12	O
:	O
the	O
whole	O
scan	O
(	O
first	O
row	O
),	O
HU	O
(	O
second	O
row	O
),	O
and	O
BF	O
maps	O
(	O
third	O
row	O
)	O
ordered	O
from	O
(	O
a	O
)	O
to	O
(	O
e	O
)	O
according	O
to	O
the	O
scan	O
position	O
(	O
the	O
third	O
section	O
is	O
the	O
central	O
one	O
).	O

The	O
BF	O
maps	O
are	O
visualized	O
using	O
the	O
same	O
colour	O
scale	O
.	O

By	O
chance	O
,	O
they	O
are	O
also	O
sorted	O
according	O
to	O
their	O
E	O
value	O
:	O
Es	O
=	O
7	O
.	O
48	O
(	O
a	O
),	O
Es	O
=	O
7	O
.	O
64	O
(	O
b	O
),	O
Es	O
=	O
7	O
.	O
86	O
(	O
c	O
),	O
Es	O
=	O
8	O
.	O
01	O
(	O
d	O
),	O
Es	O
=	O
8	O
.	O
37	O
(	O
e	O
).	O

BF	O
maps	O
of	O
the	O
four	O
consecutive	O
slices	O
of	O
ID6	O
-	O
FU3	O
(	O
1	O
–	O
4	O
,	O
from	O
(	O
a	O
)	O
to	O
(	O
d	O
)).	O
μw	O
=	O
44	O
.	O
4	O
,	O
Mw	O
=	O
37	O
.	O
8	O
.	O

BF	O
maps	O
of	O
the	O
five	O
consecutive	O
slices	O
of	O
ID6	O
-	O
FU4	O
(	O
1	O
–	O
5	O
,	O
from	O
(	O
a	O
)	O
to	O
(	O
e	O
)).	O
μw	O
=	O
39	O
.	O
2	O
,	O
Mw	O
=	O
33	O
.	O
2	O
.	O

BF	O
maps	O
of	O
the	O
five	O
consecutive	O
slices	O
of	O
ID11	O
-	O
FU4	O
(	O
1	O
–	O
5	O
,	O
from	O
(	O
a	O
)	O
to	O
(	O
e	O
)).	O
μw	O
=	O
72	O
.	O
3	O
,	O
Mw	O
=	O
63	O
.	O
3	O
.	O

BF	O
maps	O
of	O
the	O
four	O
consecutive	O
slices	O
(	O
1	O
–	O
4	O
,	O
from	O
(	O
a	O
)	O
to	O
(	O
d	O
))	O
composing	O
lesions	O
ID11	O
,	O
baseline	O
(	O
μw	O
=	O
80	O
.	O
0	O
,	O
first	O
row	O
)	O
and	O
lesion	O
ID6	O
-	O
FU1	O
(	O
μw	O
=	O
77	O
.	O
5	O
,	O
second	O
row	O
).	O
μw	O
'	O
s	O
are	O
statistically	O
equivalent	O
.	O

BF	O
maps	O
of	O
the	O
five	O
consecutive	O
slices	O
(	O
1	O
–	O
5	O
,	O
from	O
(	O
a	O
)	O
to	O
(	O
e	O
))	O
composing	O
lesions	O
ID3	O
,	O
baseline	O
(	O
μw	O
=	O
111	O
.	O
8	O
,	O
first	O
row	O
)	O
and	O
lesion	O
ID2	O
-	O
FU1	O
(	O
μw	O
=	O
112	O
.	O
8	O
,	O
second	O
row	O
).	O
μw	O
'	O
s	O
are	O
statistically	O
equivalent	O
.	O

Histograms	O
of	O
entropies	O
Es	O
of	O
all	O
slices	O
for	O
baseline	O
(	O
a	O
)	O
and	O
FU	O
(	O
b	O
)	O
examinations	O
.	O

Mean	O
values	O
,	O
highlighted	O
by	O
the	O
vertical	O
red	O
lines	O
,	O
are	O
7	O
.	O
4	O
and	O
6	O
.	O
9	O
,	O
respectively	O
.	O

Summary	O
of	O
measures	O
for	O
slices	O
and	O
whole	O
tumour	B-DS
referred	O
to	O
baseline	O
CTp	O
examinations	O
:	O
entropy	O
(	O
E	O
),	O
mean	O
(	O
μ	O
),	O
and	O
median	O
(	O
M	O
)	O
BF	O
values	O
,	O
where	O
the	O
subscripts	O
s	O
and	O
w	O
stand	O
for	O
slice	O
or	O
whole	O
,	O
respectively	O
.	O

For	O
the	O
whole	O
tumour	B-DS
,	O
r	O
of	O
each	O
slice	O
-	O
based	O
measure	O
is	O
computed	O
as	O
well	O
.	O

Italicized	O
and	O
bold	O
-	O
italicized	O
values	O
point	O
out	O
minimum	O
and	O
maximum	O
value	O
of	O
a	O
given	O
measure	O
,	O
respectively	O
.	O

Bold	O
nonitalicized	O
values	O
highlight	O
an	O
equivalence	O
between	O
μs	O
and	O
μw	O
,	O
or	O
Ms	O
and	O
Mw	O
.	O

Baseline	O
examinations	O

Patient	O

Slice	O

Whole	O
tumor	O

Measure	O

1	O

2	O

3	O

4	O

5	O

Measure	O

Value	O

r	O

ID1	O

E	O
s	O

7	O
.	O
27	O

7	O
.	O
27	O

7	O
.	O
26	O

6	O
.	O
75	O

6	O
.	O
61	O

E	O
w	O

7	O
.	O
14	O

0	O
.	O
66	O

μ	O
s	O

67	O
.	O
9	O

62	O
.	O
9	O

62	O
.	O
3	O

45	O
.	O
8	O

40	O
.	O
5	O

μ	O
w	O

56	O
.	O
0	O

27	O
.	O
4	O

M	O
s	O

56	O
.	O
9	O

50	O
.	O
9	O

45	O
.	O
7	O

33	O
.	O
8	O

28	O
.	O
4	O

M	O
w	O

41	O
.	O
4	O

28	O
.	O
5	O


ID2	O

E	O
s	O

8	O
.	O
17	O

8	O
.	O
15	O

8	O
.	O
22	O

8	O
.	O
05	O

7	O
.	O
91	O

E	O
w	O

8	O
.	O
20	O

0	O
.	O
31	O

μ	O
s	O

124	O
.	O
1	O

115	O
.	O
8	O

128	O
.	O
5	O

118	O
.	O
2	O

108	O
.	O
3	O

μ	O
w	O

120	O
.	O
1	O

20	O
.	O
2	O

M	O
s	O

107	O
.	O
3	O

96	O
.	O
6	O

110	O
.	O
8	O

99	O
.	O
8	O

93	O
.	O
2	O

M	O
w	O

102	O
.	O
0	O

17	O
.	O
6	O


ID3	O

E	O
s	O

7	O
.	O
81	O

7	O
.	O
75	O

7	O
.	O
89	O

7	O
.	O
85	O

7	O
.	O
67	O

E	O
w	O

7	O
.	O
87	O

0	O
.	O
23	O

μ	O
s	O

117	O
.	O
6	O

111	O
.	O
3	O

116	O
.	O
4	O

115	O
.	O
1	O

102	O
.	O
3	O

μ	O
w	O

111	O
.	O
8	O

15	O
.	O
2	O

M	O
s	O

101	O
.	O
3	O

103	O
.	O
1	O

102	O
.	O
4	O

103	O
.	O
7	O

93	O
.	O
5	O

M	O
w	O

100	O
.	O
1	O

10	O
.	O
2	O


ID4	O

E	O
s	O

7	O
.	O
26	O

7	O
.	O
38	O

7	O
.	O
31	O

7	O
.	O
36	O

7	O
.	O
44	O

E	O
w	O

7	O
.	O
39	O

0	O
.	O
18	O

μ	O
s	O

65	O
.	O
7	O

69	O
.	O
7	O

65	O
.	O
1	O

68	O
.	O
1	O

71	O
.	O
2	O

μ	O
w	O

68	O
.	O
0	O

6	O
.	O
1	O

M	O
s	O

54	O
.	O
9	O

56	O
.	O
9	O

47	O
.	O
9	O

50	O
.	O
0	O

53	O
.	O
6	O

M	O
w	O

52	O
.	O
8	O

9	O
.	O
0	O


ID5	O

E	O
s	O

7	O
.	O
81	O

7	O
.	O
84	O

7	O
.	O
36	O

6	O
.	O
60	O

7	O
.	O
79	O

E	O
w	O

7	O
.	O
70	O

1	O
.	O
23	O

μ	O
s	O

115	O
.	O
1	O

106	O
.	O
8	O

80	O
.	O
7	O

43	O
.	O
2	O

107	O
.	O
3	O

μ	O
w	O

87	O
.	O
2	O

71	O
.	O
8	O

M	O
s	O

93	O
.	O
2	O

87	O
.	O
1	O

67	O
.	O
4	O

38	O
.	O
2	O

90	O
.	O
6	O

M	O
w	O

67	O
.	O
6	O

55	O
.	O
0	O


ID6	O

E	O
s	O

6	O
.	O
10	O

5	O
.	O
96	O

6	O
.	O
38	O

6	O
.	O
62	O

6	O
.	O
59	O

E	O
w	O

6	O
.	O
54	O

0	O
.	O
66	O

μ	O
s	O

33	O
.	O
3	O

31	O
.	O
7	O

41	O
.	O
3	O

52	O
.	O
7	O

63	O
.	O
9	O

μ	O
w	O

42	O
.	O
9	O

32	O
.	O
2	O

M	O
s	O

27	O
.	O
5	O

28	O
.	O
5	O

34	O
.	O
5	O

47	O
.	O
0	O

58	O
.	O
8	O

M	O
w	O

36	O
.	O
8	O

31	O
.	O
3	O


ID7	O

E	O
s	O

6	O
.	O
37	O

6	O
.	O
27	O

6	O
.	O
53	O

—	O

—	O

E	O
w	O

6	O
.	O
67	O

0	O
.	O
26	O

μ	O
s	O

46	O
.	O
2	O

38	O
.	O
2	O

60	O
.	O
9	O

—	O

—	O

μ	O
w	O

47	O
.	O
9	O

22	O
.	O
7	O

M	O
s	O

38	O
.	O
6	O

30	O
.	O
5	O

55	O
.	O
3	O

—	O

—	O

M	O
w	O

40	O
.	O
7	O

24	O
.	O
8	O


ID8	O

E	O
s	O

7	O
.	O
43	O

7	O
.	O
07	O

8	O
.	O
10	O

7	O
.	O
92	O

7	O
.	O
62	O

E	O
w	O

7	O
.	O
95	O

1	O
.	O
03	O

μ	O
s	O

74	O
.	O
9	O

61	O
.	O
5	O

138	O
.	O
4	O

156	O
.	O
0	O

118	O
.	O
6	O

μ	O
w	O

105	O
.	O
2	O

94	O
.	O
5	O

M	O
s	O

57	O
.	O
1	O

53	O
.	O
9	O

119	O
.	O
0	O

141	O
.	O
7	O

104	O
.	O
1	O

M	O
w	O

85	O
.	O
3	O

87	O
.	O
8	O


ID9	O

E	O
s	O

8	O
.	O
54	O

7	O
.	O
59	O

7	O
.	O
65	O

8	O
.	O
03	O

8	O
.	O
53	O

E	O
w	O

8	O
.	O
24	O

0	O
.	O
95	O

μ	O
s	O

175	O
.	O
7	O

79	O
.	O
6	O

81	O
.	O
4	O

104	O
.	O
6	O

160	O
.	O
1	O

μ	O
w	O

118	O
.	O
4	O

96	O
.	O
1	O

M	O
s	O

158	O
.	O
3	O

60	O
.	O
0	O

62	O
.	O
3	O

73	O
.	O
0	O

133	O
.	O
2	O

M	O
w	O

88	O
.	O
9	O

98	O
.	O
3	O


ID10	O

E	O
s	O

6	O
.	O
75	O

6	O
.	O
66	O

6	O
.	O
42	O

6	O
.	O
52	O

6	O
.	O
76	O

E	O
w	O

6	O
.	O
66	O

0	O
.	O
34	O

μ	O
s	O

45	O
.	O
9	O

44	O
.	O
2	O

38	O
.	O
2	O

40	O
.	O
8	O

48	O
.	O
5	O

μ	O
w	O

43	O
.	O
4	O

10	O
.	O
3	O

M	O
s	O

37	O
.	O
8	O

37	O
.	O
3	O

32	O
.	O
5	O

34	O
.	O
6	O

42	O
.	O
6	O

M	O
w	O

36	O
.	O
4	O

10	O
.	O
1	O


ID11	O

E	O
s	O

7	O
.	O
46	O

7	O
.	O
34	O

6	O
.	O
89	O

7	O
.	O
63	O

—	O

E	O
w	O

7	O
.	O
50	O

0	O
.	O
74	O

μ	O
s	O

92	O
.	O
2	O

80	O
.	O
7	O

58	O
.	O
9	O

92	O
.	O
6	O

—	O

μ	O
w	O

80	O
.	O
0	O

33	O
.	O
8	O

M	O
s	O

76	O
.	O
5	O

61	O
.	O
4	O

51	O
.	O
3	O

74	O
.	O
1	O

—	O

M	O
w	O

63	O
.	O
3	O

25	O
.	O
2	O


ID12	O

E	O
s	O

7	O
.	O
48	O

7	O
.	O
64	O

7	O
.	O
86	O

8	O
.	O
01	O

8	O
.	O
37	O

E	O
w	O

8	O
.	O
07	O

0	O
.	O
89	O

μ	O
s	O

124	O
.	O
5	O

110	O
.	O
0	O

113	O
.	O
6	O

116	O
.	O
8	O

157	O
.	O
4	O

μ	O
w	O

125	O
.	O
0	O

47	O
.	O
4	O

M	O
s	O

118	O
.	O
7	O

106	O
.	O
1	O

104	O
.	O
0	O

112	O
.	O
7	O

145	O
.	O
9	O

M	O
w	O

116	O
.	O
0	O

41	O
.	O
9	O

Summary	O
of	O
measures	O
for	O
slices	O
and	O
whole	O
tumour	B-DS
referred	O
to	O
FU	O
CTp	O
examinations	O
.	O

Notations	O
are	O
the	O
same	O
as	O
those	O
in	O
Table	O
1	O
.	O

Here	O
,	O
the	O
FU	O
number	O
is	O
also	O
reported	O
.	O

Follow	O
-	O
up	O
examinations	O

Patient	O

FU	O

Measure	O

Slice	O

Whole	O
tumour	B-DS

1	O

2	O

3	O

4	O

5	O

Measure	O

Value	O

r	O

ID2	O

1	O

E	O
s	O

7	O
.	O
85	O

8	O
.	O
06	O

7	O
.	O
99	O

7	O
.	O
88	O

7	O
.	O
72	O

E	O
w	O

8	O
.	O
08	O

0	O
.	O
34	O

μ	O
s	O

99	O
.	O
6	O

130	O
.	O
6	O

118	O
.	O
3	O

111	O
.	O
4	O

97	O
.	O
6	O

μ	O
w	O

112	O
.	O
8	O

33	O
.	O
0	O

M	O
s	O

85	O
.	O
2	O

110	O
.	O
4	O

99	O
.	O
9	O

85	O
.	O
6	O

75	O
.	O
2	O

M	O
w	O

92	O
.	O
4	O

35	O
.	O
2	O


ID6	O

1	O

E	O
s	O

6	O
.	O
50	O

6	O
.	O
26	O

7	O
.	O
33	O

7	O
.	O
70	O

—	O

E	O
w	O

7	O
.	O
50	O

1	O
.	O
44	O

μ	O
s	O

47	O
.	O
7	O

38	O
.	O
0	O

76	O
.	O
8	O

145	O
.	O
6	O

—	O

μ	O
w	O

77	O
.	O
5	O

107	O
.	O
6	O

M	O
s	O

41	O
.	O
1	O

33	O
.	O
6	O

70	O
.	O
4	O

120	O
.	O
7	O

—	O

M	O
w	O

60	O
.	O
1	O

87	O
.	O
1	O

2	O

E	O
s	O

6	O
.	O
63	O

6	O
.	O
21	O

6	O
.	O
40	O

6	O
.	O
90	O

—	O

E	O
w	O

6	O
.	O
82	O

0	O
.	O
69	O

μ	O
s	O

58	O
.	O
1	O

42	O
.	O
2	O

45	O
.	O
8	O

80	O
.	O
0	O

—	O

μ	O
w	O

53	O
.	O
5	O

37	O
.	O
8	O

M	O
s	O

49	O
.	O
2	O

38	O
.	O
6	O

32	O
.	O
5	O

71	O
.	O
4	O

—	O

M	O
w	O

43	O
.	O
2	O

38	O
.	O
9	O

3	O

E	O
s	O

6	O
.	O
37	O

6	O
.	O
26	O

6	O
.	O
73	O

6	O
.	O
43	O

—	O

E	O
w	O

6	O
.	O
67	O

0	O
.	O
47	O

μ	O
s	O

40	O
.	O
8	O

40	O
.	O
9	O

45	O
.	O
7	O

54	O
.	O
6	O

—	O

μ	O
w	O

44	O
.	O
4	O

13	O
.	O
8	O

M	O
s	O

33	O
.	O
3	O

36	O
.	O
9	O

36	O
.	O
3	O

50	O
.	O
4	O

—	O

M	O
w	O

37	O
.	O
8	O

17	O
.	O
1	O

4	O

E	O
s	O

6	O
.	O
42	O

6	O
.	O
31	O

6	O
.	O
49	O

6	O
.	O
42	O

6	O
.	O
18	O

E	O
w	O

6	O
.	O
45	O

0	O
.	O
31	O

μ	O
s	O

42	O
.	O
7	O

38	O
.	O
1	O

40	O
.	O
3	O

39	O
.	O
3	O

35	O
.	O
3	O

μ	O
w	O

39	O
.	O
2	O

7	O
.	O
3	O

M	O
s	O

38	O
.	O
6	O

31	O
.	O
8	O

32	O
.	O
8	O

33	O
.	O
2	O

30	O
.	O
6	O

M	O
w	O

33	O
.	O
2	O

8	O
.	O
0	O

5	O

E	O
s	O

7	O
.	O
47	O

6	O
.	O
14	O

5	O
.	O
94	O

5	O
.	O
64	O

5	O
.	O
75	O

E	O
w	O

6	O
.	O
50	O

1	O
.	O
84	O

μ	O
s	O

96	O
.	O
1	O

33	O
.	O
3	O

24	O
.	O
7	O

19	O
.	O
9	O

24	O
.	O
7	O

μ	O
w	O

35	O
.	O
8	O

76	O
.	O
3	O

M	O
s	O

91	O
.	O
8	O

29	O
.	O
1	O

19	O
.	O
4	O

16	O
.	O
4	O

21	O
.	O
7	O

M	O
w	O

24	O
.	O
7	O

75	O
.	O
4	O


ID7	O

1	O

E	O
s	O

7	O
.	O
57	O

6	O
.	O
57	O

7	O
.	O
20	O

—	O

—	O

E	O
w	O

7	O
.	O
64	O

1	O
.	O
00	O

μ	O
s	O

145	O
.	O
5	O

52	O
.	O
2	O

97	O
.	O
7	O

—	O

—	O

μ	O
w	O

95	O
.	O
5	O

93	O
.	O
3	O

M	O
s	O

133	O
.	O
8	O

42	O
.	O
6	O

78	O
.	O
4	O

—	O

—	O

M	O
w	O

78	O
.	O
4	O

91	O
.	O
2	O

2	O

E	O
s	O

5	O
.	O
82	O

6	O
.	O
33	O

5	O
.	O
90	O

—	O

—	O

E	O
w	O

6	O
.	O
33	O

0	O
.	O
51	O

μ	O
s	O

34	O
.	O
1	O

48	O
.	O
8	O

58	O
.	O
0	O

—	O

—	O

μ	O
w	O

45	O
.	O
0	O

23	O
.	O
8	O

M	O
s	O

32	O
.	O
2	O

42	O
.	O
8	O

56	O
.	O
7	O

—	O

—	O

M	O
w	O

39	O
.	O
8	O

24	O
.	O
4	O


ID9	O

1	O

E	O
s	O

7	O
.	O
45	O

6	O
.	O
47	O

6	O
.	O
60	O

6	O
.	O
50	O

6	O
.	O
58	O

E	O
w	O

6	O
.	O
80	O

0	O
.	O
98	O

μ	O
s	O

80	O
.	O
8	O

36	O
.	O
9	O

45	O
.	O
1	O

38	O
.	O
7	O

41	O
.	O
6	O

μ	O
w	O

46	O
.	O
2	O

43	O
.	O
8	O

M	O
s	O

67	O
.	O
6	O

31	O
.	O
4	O

39	O
.	O
6	O

34	O
.	O
1	O

36	O
.	O
2	O

M	O
w	O

38	O
.	O
4	O

36	O
.	O
2	O


ID11	O

1	O

E	O
s	O

7	O
.	O
04	O

6	O
.	O
83	O

6	O
.	O
63	O

7	O
.	O
46	O

—	O

E	O
w	O

7	O
.	O
20	O

0	O
.	O
83	O

μ	O
s	O

71	O
.	O
4	O

54	O
.	O
7	O

50	O
.	O
4	O

108	O
.	O
4	O

—	O

μ	O
w	O

66	O
.	O
9	O

58	O
.	O
0	O

M	O
s	O

60	O
.	O
7	O

47	O
.	O
3	O

44	O
.	O
6	O

96	O
.	O
5	O

—	O

M	O
w	O

55	O
.	O
5	O

51	O
.	O
9	O

2	O

E	O
s	O

6	O
.	O
77	O

6	O
.	O
66	O

7	O
.	O
26	O

7	O
.	O
49	O

7	O
.	O
53	O

E	O
w	O

7	O
.	O
40	O

0	O
.	O
87	O

μ	O
s	O

52	O
.	O
4	O

43	O
.	O
3	O

67	O
.	O
7	O

90	O
.	O
9	O

107	O
.	O
9	O

μ	O
w	O

70	O
.	O
2	O

64	O
.	O
6	O

M	O
s	O

41	O
.	O
7	O

33	O
.	O
6	O

55	O
.	O
6	O

84	O
.	O
0	O

95	O
.	O
9	O

M	O
w	O

56	O
.	O
5	O

62	O
.	O
3	O

3	O

E	O
s	O

7	O
.	O
20	O

7	O
.	O
17	O

7	O
.	O
30	O

7	O
.	O
49	O

—	O

E	O
w	O

7	O
.	O
40	O

0	O
.	O
32	O

μ	O
s	O

74	O
.	O
8	O

73	O
.	O
2	O

75	O
.	O
9	O

90	O
.	O
5	O

—	O

μ	O
w	O

78	O
.	O
1	O

17	O
.	O
3	O

M	O
s	O

70	O
.	O
4	O

66	O
.	O
2	O

69	O
.	O
7	O

81	O
.	O
0	O

—	O

M	O
w	O

71	O
.	O
0	O

14	O
.	O
8	O

4	O

E	O
s	O

7	O
.	O
05	O

7	O
.	O
20	O

7	O
.	O
22	O

7	O
.	O
28	O

7	O
.	O
32	O

E	O
w	O

7	O
.	O
29	O

0	O
.	O
27	O

μ	O
s	O

69	O
.	O
0	O

72	O
.	O
9	O

70	O
.	O
9	O

71	O
.	O
5	O

79	O
.	O
0	O

μ	O
w	O

72	O
.	O
3	O

10	O
.	O
1	O

M	O
s	O

64	O
.	O
3	O

64	O
.	O
1	O

60	O
.	O
1	O

61	O
.	O
1	O

70	O
.	O
1	O

M	O
w	O

63	O
.	O
3	O

10	O
.	O
0	O

5	O

E	O
s	O

7	O
.	O
57	O

7	O
.	O
39	O

7	O
.	O
52	O

7	O
.	O
87	O

8	O
.	O
24	O

E	O
w	O

7	O
.	O
81	O

0	O
.	O
85	O

μ	O
s	O

80	O
.	O
9	O

71	O
.	O
7	O

76	O
.	O
7	O

99	O
.	O
9	O

144	O
.	O
7	O

μ	O
w	O

90	O
.	O
1	O

73	O
.	O
0	O

M	O
s	O

60	O
.	O
7	O

55	O
.	O
2	O

61	O
.	O
3	O

74	O
.	O
2	O

123	O
.	O
2	O

M	O
w	O

66	O
.	O
8	O

68	O
.	O
0	O

